TWI825163B - 四環性化合物的製造方法 - Google Patents

四環性化合物的製造方法 Download PDF

Info

Publication number
TWI825163B
TWI825163B TW108131697A TW108131697A TWI825163B TW I825163 B TWI825163 B TW I825163B TW 108131697 A TW108131697 A TW 108131697A TW 108131697 A TW108131697 A TW 108131697A TW I825163 B TWI825163 B TW I825163B
Authority
TW
Taiwan
Prior art keywords
formula
compound
group
compound represented
reaction
Prior art date
Application number
TW108131697A
Other languages
English (en)
Chinese (zh)
Other versions
TW202024050A (zh
Inventor
芹澤宏希
川瀬朗
福田弘志
人
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202024050A publication Critical patent/TW202024050A/zh
Application granted granted Critical
Publication of TWI825163B publication Critical patent/TWI825163B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW108131697A 2018-09-04 2019-09-03 四環性化合物的製造方法 TWI825163B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018165313 2018-09-04
JP2018-165313 2018-09-04

Publications (2)

Publication Number Publication Date
TW202024050A TW202024050A (zh) 2020-07-01
TWI825163B true TWI825163B (zh) 2023-12-11

Family

ID=69722303

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108131697A TWI825163B (zh) 2018-09-04 2019-09-03 四環性化合物的製造方法

Country Status (18)

Country Link
US (1) US11939322B2 (https=)
EP (1) EP3848361B1 (https=)
JP (1) JP7167171B2 (https=)
KR (1) KR102635225B1 (https=)
CN (1) CN112585126B (https=)
AR (1) AR116113A1 (https=)
AU (1) AU2019337018B2 (https=)
BR (1) BR112021001145A2 (https=)
CA (1) CA3107270A1 (https=)
ES (1) ES3010145T3 (https=)
HR (1) HRP20250284T1 (https=)
HU (1) HUE070227T2 (https=)
IL (1) IL281079B2 (https=)
MX (1) MX2021002311A (https=)
PL (1) PL3848361T3 (https=)
SG (1) SG11202100983XA (https=)
TW (1) TWI825163B (https=)
WO (1) WO2020050241A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4285907A4 (en) 2021-01-29 2024-11-13 Chugai Seiyaku Kabushiki Kaisha Drug composition for treating pediatric cancers
CN117024410A (zh) * 2023-08-15 2023-11-10 上海药坦药物研究开发有限公司 一种艾乐替尼中间体及其制备方法
WO2025067412A1 (zh) * 2023-09-28 2025-04-03 重庆博腾制药科技股份有限公司 一种抗肿瘤药物中间体的制备方法
CN120081779A (zh) * 2025-02-19 2025-06-03 江苏天士力帝益药业有限公司 一种阿来替尼杂质01a及其控制方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201103537A (en) * 2009-06-10 2011-02-01 Chugai Pharmaceutical Co Ltd Four rings compounds

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS506987B1 (https=) 1970-02-17 1975-03-19
JPS4918630B1 (https=) 1970-07-29 1974-05-11
JPS5859712U (ja) 1981-10-16 1983-04-22 ニチバン株式会社 ラベル貼付機
JPH0892090A (ja) 1994-07-26 1996-04-09 Tanabe Seiyaku Co Ltd 医薬組成物
EP0695755B1 (en) 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazole
EA001450B1 (ru) 1996-05-01 2001-04-23 Эли Лилли Энд Компани Галогензамещенные ингибиторы протеинкиназы с
ES2292262T3 (es) * 1998-12-24 2008-03-01 Astellas Pharma Inc. Compuestos de imidazol y su uso medicinal.
EP1178988B1 (en) 1999-05-14 2007-02-28 The Australian National University Compounds and therapeutic methods
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
EP1603567A4 (en) 2003-02-28 2006-10-18 Inotek Pharmaceuticals Corp TETRACYCLIC BENZAMIDE DERIVATIVES AND METHOD OF USE THEREOF
ES2263862T3 (es) 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
JP2007513890A (ja) 2003-12-12 2007-05-31 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
TW200609215A (en) 2004-03-19 2006-03-16 Speedel Experimenta Ag Organic compounds
WO2005092062A2 (en) * 2004-03-19 2005-10-06 Myriad Genetics, Inc. Compounds for neurodegenerative disorders
JP2008502595A (ja) 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
MXPA06014066A (es) * 2004-06-02 2007-02-15 Pharmacyclics Inc Inhibicion de factor viia.
DE602005020465D1 (de) 2004-08-26 2010-05-20 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
US7091202B2 (en) 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
GB0517329D0 (en) 2005-08-25 2005-10-05 Merck Sharp & Dohme Stimulation of neurogenesis
RU2008122547A (ru) 2005-11-07 2009-12-20 Айрм Ллк (Bm) Соединения и композиции как модуляторы арпп (активированных рецепторов пролифератора пероксисом)
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
EP2142551B1 (en) 2007-04-17 2015-10-14 Bristol-Myers Squibb Company Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
PT2176231T (pt) 2007-07-20 2016-12-09 Nerviano Medical Sciences Srl Derivados de indazol substituídos activos como inibidores de quinases
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
US20110038898A1 (en) 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
MX2011011661A (es) 2009-05-07 2011-11-18 Astrazeneca Ab Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
JP5006987B2 (ja) 2010-11-22 2012-08-22 中外製薬株式会社 ４環性化合物を含む医薬
MY170904A (en) 2012-09-25 2019-09-13 Chugai Pharmaceutical Co Ltd Ret inhibitor
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 ４環性化合物の新規結晶
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有４環性化合物的製劑
WO2015193309A1 (en) 2014-06-18 2015-12-23 F. Hoffmann-La Roche Ag New pharmaceutical composition comprising non-ionic surfactants
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
CN104402862B (zh) * 2014-11-12 2016-10-05 苏州明锐医药科技有限公司 艾立替尼的制备方法
US9573932B2 (en) 2015-03-02 2017-02-21 Yong Xu Synthesis of intermediates in the preparation of ALK inhibitor
WO2017073706A1 (ja) * 2015-10-30 2017-05-04 中外製薬株式会社 ジヒドロナフト［２，３－ｂ］ベンゾフラン誘導体
CN106928184B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN106928185B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法
CN107033124B (zh) * 2017-04-21 2019-09-20 湖南博奥德药业有限公司 一种艾乐替尼的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201103537A (en) * 2009-06-10 2011-02-01 Chugai Pharmaceutical Co Ltd Four rings compounds

Also Published As

Publication number Publication date
CA3107270A1 (en) 2020-03-12
AU2019337018B2 (en) 2024-03-07
IL281079B1 (en) 2024-08-01
HUE070227T2 (hu) 2025-05-28
US20220372025A1 (en) 2022-11-24
WO2020050241A1 (ja) 2020-03-12
CN112585126B (zh) 2024-05-07
HRP20250284T1 (hr) 2025-04-25
AR116113A1 (es) 2021-03-31
EP3848361A1 (en) 2021-07-14
EP3848361C0 (en) 2025-01-22
EP3848361A4 (en) 2022-06-15
EP3848361B1 (en) 2025-01-22
TW202024050A (zh) 2020-07-01
KR20210053890A (ko) 2021-05-12
CN112585126A (zh) 2021-03-30
JPWO2020050241A1 (ja) 2021-08-30
JP7167171B2 (ja) 2022-11-08
IL281079B2 (en) 2024-12-01
PL3848361T3 (pl) 2025-07-07
AU2019337018A1 (en) 2021-03-18
SG11202100983XA (en) 2021-03-30
ES3010145T3 (en) 2025-04-01
MX2021002311A (es) 2021-04-28
BR112021001145A2 (pt) 2021-04-20
IL281079A (en) 2021-04-29
US11939322B2 (en) 2024-03-26
KR102635225B1 (ko) 2024-02-07

Similar Documents

Publication Publication Date Title
TWI825163B (zh) 四環性化合物的製造方法
JP6340391B2 (ja) 置換された５−フルオロ−１ｈ−ピラゾロピリジン類を製造するための方法
CN106946917B (zh) 一种jak抑制剂巴瑞替尼及其中间体的新合成方法
TW201825491A (zh) 製備細胞凋亡誘導劑的方法
CN116554150B (zh) 第四代egfr抑制剂
EP4069702A1 (en) Sstr5 antagonists
EP3334721B1 (en) Cgrp receptor antagonists
TWI838741B (zh) 製備ｂｔｋ抑制劑之製程
WO2016187028A1 (en) Heteroaryl compounds, synthesis thereof, and intermediates thereto
CA3139284A1 (en) Synthesis of crac channel inhibitors
HK40051429B (zh) 四环化合物的制备方法
HK40051429A (en) Method of producing tetracyclic compound
KR101865868B1 (ko) 1-이소프로필-3-[5-[1-(3-메톡시프로필) 피페리딘-4-일]-[1,3,4]옥사디아졸-2-일]-1h-인다졸 옥살레이트의 대규모 제조공정
CN119490501A (zh) 咪唑双环化合物及其制备方法和用途
WO2024262491A1 (ja) Ｎｒｆ２活性化作用を有する含窒素複素環化合物の結晶
JP2016132660A (ja) 新規イミダゾピリミジンおよびその医薬用途
WO2025136811A1 (en) Chemical compounds and uses thereof
CN116535423A (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用
JPWO2011030537A1 (ja) ４−（５−メチルピリジン−２−イルアミノ）ピペリジン−１−カルボン酸誘導体の製造方法
CN117945945A (zh) 一种gpr139受体激动剂、其制备方法及其应用
WO2010123441A1 (en) Crystalline form of 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n-propylcinnoline-3- carboxamide hydrogen sulphate, for treatment of anxiety disorders